This site is intended for health professionals only
Monday 11 December 2017
Share |

Topic: acute bacterial skin and skin structure infections

June 10, 2014
Cubist Pharmaceuticals, Inc. announced the publication of positive results from ESTABLISH-2, a pivotal phase III clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate).

Cubist Pharmaceuticals, Inc. announced the publication of positive results from ESTABLISH-2, a pivotal phase III clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate).

The drug is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine